
## Sang Joon Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2345316/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Annals of the Rheumatic Diseases, 2013, 72, 1613-1620.	0.9	575
2	A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annals of the Rheumatic Diseases, 2013, 72, 1605-1612.	0.9	531
3	Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Review of Gastroenterology and Hepatology, 2015, 9, 35-44.	3.0	100
4	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncology, The, 2017, 18, 917-928.	10.7	93
5	Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection. Clinical Therapeutics, 2021, 43. 1706-1727.	2.5	39
6	A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemotherapy and Pharmacology, 2018, 81, 505-514.	2.3	32
7	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Research and Therapy, 2021, 23, 51.	3.5	18
8	Pharmacokinetic equivalence of CTâ€₽17 to high oncentration (100Âmg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clinical and Translational Science, 2021, 14, 1280-1291.	3.1	11
9	Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Research and Treatment, 2021, 188, 631-640.	2.5	11
10	Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. BioDrugs, 2020, 34, 513-528.	4.6	10
11	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology, 2022, 61, 1385-1395.	1.9	10
12	Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness. Advances in Therapy, 2021, 38, 4366-4387.	2.9	10
13	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CTâ€P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. British Journal of Clinical Pharmacology, 2021, 87, 4323-4333.	2.4	7
14	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. Blood Advances, 2021, 5, 3354-3361.	5.2	6
15	Some thoughts on the QR method for analytical similarity evaluation. Journal of Biopharmaceutical Statistics, 2020, 30, 521-536.	0.8	2
16	Current Issues in Analytical Similarity Assessment. Statistics in Biopharmaceutical Research, 2021, 13, 203-209.	0.8	2